A few decades ago the expression "it's like comparing apples and oranges" was widely used when arguing the relative merits of 99m Tc-based radiopharmaceuticals with the more traditional 201 Tl-chloride in myocardial perfusion imaging. Recent articles in the Journal of Nuclear Medicine Technology (JNMT) highlighted that this same expression might be equally relevant when discussing the provision of nuclear medicine services across the developed world.
For many years, developed countries in the northern hemisphere have enjoyed a reliable and cost-effective supply of cyclotron-produced radionuclides, whereas those in the southern hemisphere, particularly Australia, relied on importing cyclotron-produced See J Nucl Med Technol 2010; 38:1-3, 6-17 nuclides from the northern hemisphere. In the early 1990s, the Australian National Medical Cyclotron was constructed to meet the local needs for cyclotron-produced PET and general nuclear medicine radionuclides. Unfortunately, the investment failed on both fronts, and the system was commercially decommissioned this year, leaving Australia with only a handful of compact cyclotrons dedicated to PET tracer production. Although cyclotronproduced radionuclides are readily and cost-effectively available in the northern hemisphere (e.g., 123 I-metaiodobenzylguanidine), the southern hemisphere is confronted with a relative cost-prohibition. Indeed, although most nuclear medicine texts cite the importance of 123 I in thyroid imaging, it is not generally used in Australia. The global 99m Tc crisis, however, should be more accurately described as a compartmented global crisis because the impact in the southern hemisphere has been minimal. Dated reactors and lack of new reactor installations in the northern hemisphere will produce recurring 99m Tc supply stress. Indeed, the Society of Nuclear Medicine Technologist Section (SNMTS) recently launched an awareness campaign in an attempt to protect the 99m Tc-based imaging industry. The "Got 99m Tc?" T-shirt is part of that initiative. Furthermore, cyclotrons are being looked at to produce 99m Tc more reliably (1), which casts the industry back to the pre-99 Mo/ 99m Tc generator era of daily deliveries, unreliable service (particularly after hours), and carrier-related issues with image quality. Changes to clinical practice have been proposed to accommodate the lack of 99m Tc. Because of this lack of 99m Tc, Pagnanelli and Basso reported in a recent JNMT article (2) on the clinical utility and protocols for 201 Tl myocardial perfusion studies, a regression to days gone by. The use of 67 Ga-citrateand 111 In-labeled white blood cells in preference to 99m Tc-labeled white blood cells in infection imaging provides another example. In the same journal, Buck et al. (3) reported that the proliferation of PET/CT in the United States was well in excess of global trends, perhaps a measure of funding policy and an adoption of technology not reliant on 99m Tc supply. With reference to the former, because of the much more prescriptive and restrictive policy in Australia, the United States enjoys a much greater clinical diversity of rebates than does Australia. It would be an interesting exercise to gain a snapshot of whether the global 99m Tc shortage has seen an associated increase in the number of 18 F ion bone scans or, in fact, a tendency to favor a move toward 13 N ammonia myocardial perfusion more than a regression toward 201 Tl. One consolation in this scenario is that patients are retained in nuclear medicine. Anecdotal evidence from the United Kingdom suggests that, for example, bone scanning may be performed only on a single day per week, which has encouraged a more widespread reliance on anatomic imaging. At a time when anatomic imaging is challenging traditional strongholds of nuclear medicine (e.g., cardiac CT or MRI and CTangiography for pulmonary embolism), the lack of 99m Tc provides little resistance.
In the southern hemisphere, there could not be a greater contrast. There are numerous new reactors, including in Australia and South America, and high-production capabilities in South Africa. There is no shortage of 99m Tc, and indeed, it is used in preference to cyclotron-produced radionuclides such as 67 Ga-citrate and 201 Tl. The hemispheric gap is perhaps best highlighted by the comparatively rapid adoption of 99m Tc-based radiopharmaceuticals for myocardial perfusion and the virtual absence of 123 I-and 111 In-based radiopharmaceuticals in clinical practice in Australia. Similarly, the availability of 99m Tc in the southern hemisphere sees a relative favoring of 99m Tclabeled white blood cells over 67 Gacitrate for infection imaging, of 99m Tc-sestamibi over 201 Tl-chloride in oncology, and of 99m Tc-based ventilation agents such as aerosols and Technegas (Cyclopharm) over 81m Kr (which is not clinically available). Nonetheless, at the time this article was being written Australia was suffering its own version of a 99m Tc crisis, with the national reactor closed for routine maintenance, causing shockwaves through the nuclear medicine community. Those most significantly affected suffered 2 weeks of lower yields on 99 Mo/ 99m Tc generators (e.g., in one of the worst cases drawn to our attention, the department in question received only 60% of its anticipated calibrated activity). Furthermore, those relying on centralized pharmacies had dose-capping measures used-for example, a 10% reduction in dispensed doses across the board. Locally, the shockwaves appeared more severe than the reality because 99 Mo has enjoyed a large production surplus for many years, with generators routinely topped up and leaving departments counting on larger activities than ordered and paid for. In fact, previous global 99m Tc crises have simply seen Australian departments get the activity ordered and paid for (rather than the higher yields consumers have become accustomed to due to the ''topped up'' generator activities).
Although the United States enjoys 6.5 PET/CT scanners per million people and Europe has 1.2 PET/CT scanners per million people (3), Australia gets by with fewer than 0.5 PET/CT scanners per million people. Furthermore, states such as Texas, Florida, New York, and Pennsylvania have populations less than that of Australia, yet each has between 10 and 16 times more PET/CT scanners servicing its population. Thus, the relative abundance of 99m Tc might be offset by a relative absence of other novel non-99m Tc SPECT tracers and scarcity of PET/CT services. Moreover, the bulk of the medical literature globally reflects practice in the northern hemisphere, and the discordance between the hemispheres may not be reflected in the literature. Consequently, the scourge that is the 99m Tc crisis in the northern hemisphere may be perceived as a global issue and change referral patterns and clinical practice unnecessarily in the southern hemisphere. Conversely, the expectation in the southern hemisphere for access to PET/CT services or novel tracers might fall frustratingly short of the actual capabilities.
A comparison of nuclear medicine status and service provision between the 2 hemispheres highlights different capabilities and different barriers, and these are not always reflected in the typically northern hemispheric-driven journal publications. A comparison of nuclear medicine status and service provision between the 2 hemispheres is like comparing apples and oranges, or perhaps baseball and cricket.
